This article discusses a serious childhood diagnosis with honesty and compassion. If you're a parent facing this, please lean on your care team and the support resources available to you — you don't have to navigate this alone.
Diffuse intrinsic pontine glioma (DIPG) — now classified as a type of diffuse midline glioma — is one of the most challenging diagnoses in pediatric medicine. We believe families deserve honest information delivered with care, alongside an understanding of where new hope is emerging.
What it is DIPG arises in the pons, a part of the brainstem that controls vital functions like breathing, heart rate, swallowing, eye movement, and balance. Because the tumor grows within and between the normal nerve fibers of the brainstem — rather than as a removable mass — it cannot be surgically removed. Most diffuse midline gliomas carry a specific genetic change called the H3 K27M mutation, which defines this tumor type under the current WHO classification and places it at grade 4.
Symptoms Because of where it grows, DIPG often causes double vision, facial weakness, difficulty swallowing, unsteadiness, and weakness on one side of the body, frequently developing over weeks.
Treatment Radiation therapy is the standard of care and is the most effective treatment for controlling the tumor and relieving symptoms — often producing a meaningful, though temporary, period of improvement. Standard chemotherapy has not proven effective for DIPG. Because outcomes with standard treatment remain poor, clinical trials are especially important, and many families choose to pursue them.
Where new hope is emerging Research has accelerated. Dordaviprone (Modeyso) received FDA accelerated approval in 2025 as the first systemic therapy for H3 K27M-mutant diffuse midline glioma that has progressed after prior treatment — a genuine milestone for a disease that has had so few options. Many other approaches, including targeted therapies and immunotherapies, are under active study.
Honest outlook, real support DIPG remains a very serious diagnosis, and median survival with current treatment is often around a year — though every child is different. Alongside tumor-directed treatment, supportive and palliative care is essential to help children feel as well as possible and to support the whole family. Palliative care is not giving up; it works alongside treatment to maximize comfort and quality of life.
If your family is facing this, please know that compassionate teams, specialized centers, and dedicated researchers are working for your child. Your care team can help you understand the options, including clinical trials, and ensure your child is supported every step of the way.